Basiliximab
- Generic Name
- Basiliximab
- Brand Names
- Simulect
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 179045-86-4
- Unique Ingredient Identifier
- 9927MT646M
- Background
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cel...
- Indication
For prophylactic treatment of kidney transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 30
- Registration Number
- NCT02730715
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Associação Médico Espírita de Botucatu
- Target Recruit Count
- 48
- Registration Number
- NCT02683291
Effect of SVF Derived MSC in DCD Renal Transplantation
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02492490
- Locations
- 🇨🇳
Fuzhou General Hospital, Xiamen Univ, Fuzhou, Fujian, China
Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
- Conditions
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT02464878
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea
- Conditions
- Interventions
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT02459977
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
DC Migration Study for Newly-Diagnosed GBM
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
- Target Recruit Count
- 64
- Registration Number
- NCT02366728
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation
- Conditions
- Interventions
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 59
- Registration Number
- NCT02123108
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Interventions
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Emory University
- Target Recruit Count
- 31
- Registration Number
- NCT01884571
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT01780844
- Locations
- 🇺🇸
Site US10038, Pittsburgh, Pennsylvania, United States
🇺🇸Site US10007, Atlanta, Georgia, United States
🇺🇸Site US10018, Chicago, Illinois, United States
A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 188
- Registration Number
- NCT01625377
- Locations
- 🇫🇷
Novartis Investigative Site, Villejuif, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.